Eli Lilly to Invest $3 Billion in New Manufacturing Facility in the Netherlands

Eli Lilly and Company has announced plans to invest $3 billion in a new manufacturing facility in Katwijk, located within the Leiden Bio Science Park in the Netherlands. The initiative aims to expand Lilly’s production capacity for oral medicines and strengthen its global manufacturing network. The investment remains subject to local and regulatory approvals.

Boosting GLP-1 Production Capacity

The new facility will enhance Lilly’s ability to produce large volumes of oral treatments, including orforglipron, the company’s first small-molecule GLP-1 receptor agonist for metabolic disorders like diabetes and obesity. This development aligns with rising global demand for GLP-1 therapies and demonstrates the company’s strategic focus on innovation and scalability.

Strengthening European Biopharma Presence

By situating its new facility in one of Europe’s leading biotech clusters, Lilly is deepening its European footprint and reinforcing its commitment to advanced pharmaceutical manufacturing. The investment also highlights the growing importance of Leiden Bio Science Park as a hub for next-generation biopharma research and production.